Laden…
1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one
Ketobemidone is a synthetic opioid primarily used as a strong analgesic. It acts primarily as an agonist at the μ-opioid receptor and possesses analgesic as well as sedative properties. Due to its potential for dependence and the risks of respiratory depression, careful handling is required. The substance is medically used for the treatment of severe pain.
Class
Phenylpiperidine
Pharmacological context
Mechanism
μ-opioid receptor agonist
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Ketobemidone acts through the following pharmacological mechanisms:
Designations
IUPAC: 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidyl]propan-1-one
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der Serotonintransporter (SERT/5-HTT) ist ein Natrium-abhängiger Monoamintransporter, der Serotonin aus dem synaptischen Spalt zurück in die präsynaptische Zelle transportiert. Er ist das primäre Ziel von SSRI und MDMA.
Der Noradrenalintransporter (NET) ist ein Monoamintransporter, der Noradrenalin aus dem synaptischen Spalt zurücktransportiert. Er wird von verschiedenen Stimulants und Antidepressiva beeinflusst.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulants und spielt eine Schlüsselrolle im Belohnungssystem.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 20–40 mg
Total duration 4–6 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 10–20 mg |
| Reported | 20–40 mg |
| Strong | 40–80 mg |
IV
| Tier | Dosage |
|---|---|
| Light | 1–2 mg |
| Reported | 2–5 mg |
| Strong | 5–10 mg |
Onset
15–30 minutes
Peak
1–2 hours
Total duration
4–6 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Risiko von Atemdepression und Abhängigkeit.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.